Skip to main content
SpringerLink
Log in
Book cover

The Tumor Immunoenvironment pp 585–602Cite as

Therapeutic Targeting Regulatory T Cells in Tumor

  • Chapter
  • First Online:

  • 2225 Accesses

Abstract

Cancer cells express a range of tumor associated antigens (TAA) including self-antigens, which should engender TAA-specific immune response to dampen tumor progression and result in tumor eradiation. However, this is rarely happened in patients with cancer. It is thought that active immunosuppressive network in the cancer microenvironment hinders anti-tumor immunity. Regulatory T cells (Tregs) are an important component in the immune suppressive network, suppress TAA-specific T cell anti-tumor immunity and are one of the main obstacles tempering successful immunotherapy and active vaccination. In this chapter, we focus on Tregs, review their characteristics and suppressive mechanisms in the tumor microenvironment, and summarize recent development in the Treg-targeted immunotherapeutic regimens.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Amedei A, Della Bella C, Silvestri E, Prisco D, D’Elios MM (2012) T cells in gastric cancer: friends or foes. Clin Dev Immunol 2012:690571

    Article  PubMed  Google Scholar 

  • Andersen MH, Sorensen RB, Brimnes MK, Svane IM, Becker JC, thor Straten P (2009) Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J Clin Invest. 119:2245–2256

    Article  PubMed  CAS  Google Scholar 

  • Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D et al (2009) Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 15:6446–6453

    Article  PubMed  CAS  Google Scholar 

  • Anz D, Mueller W, Golic M, Kunz WG, Rapp M, Koelzer VH et al (2011) CD103 is a hallmark of tumor-infiltrating regulatory T cells. Int J Cancer 129:2417–2426

    Article  PubMed  CAS  Google Scholar 

  • Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I (2010) Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 37:508–516

    Article  PubMed  CAS  Google Scholar 

  • Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA (2005) Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 28:582–592

    Article  PubMed  CAS  Google Scholar 

  • Awwad M, North RJ (1988) Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology 65:87–92

    PubMed  CAS  Google Scholar 

  • Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L et al (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27:20–21

    Article  PubMed  CAS  Google Scholar 

  • Berd D, Mastrangelo MJ (1988) Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res 48:1671–1675

    PubMed  CAS  Google Scholar 

  • Berendt MJ, North RJ (1980) T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151:69–80

    Article  PubMed  CAS  Google Scholar 

  • Berezhnaya NM (2010) Interaction between tumor and immune system: the role of tumor cell biology. Exp Oncol 32:159–166

    PubMed  CAS  Google Scholar 

  • Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R et al (2007) Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110:1225–1232

    Article  PubMed  CAS  Google Scholar 

  • Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167–3175

    Article  PubMed  CAS  Google Scholar 

  • Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465

    Article  PubMed  CAS  Google Scholar 

  • Bursuker I, North RJ (1984) Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity. J Exp Med 159:1312–1321

    Article  PubMed  CAS  Google Scholar 

  • Byrne WL, Mills KH, Lederer JA, O’Sullivan GC (2011) Targeting regulatory T cells in cancer. Cancer Res 71:6915–6920

    Article  PubMed  CAS  Google Scholar 

  • Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B et al (2009) Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 27:1075–1081

    Article  PubMed  CAS  Google Scholar 

  • Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR et al (2007) Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27:635–646

    Article  PubMed  CAS  Google Scholar 

  • Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H et al (2005) Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A 102:419–424

    Article  PubMed  CAS  Google Scholar 

  • Chung DJ, Rossi M, Romano E, Ghith J, Yuan J, Munn DH et al (2009) Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 114:555–563

    Article  PubMed  CAS  Google Scholar 

  • Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim SC et al (2010) Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS ONE 5:e10436

    Article  PubMed  CAS  Google Scholar 

  • Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM et al (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450:566–569

    Article  PubMed  CAS  Google Scholar 

  • Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J et al (2010) IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 11:1093–1101

    Article  PubMed  CAS  Google Scholar 

  • Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P et al (2003) Blockade of B7–H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9:562–567

    Article  PubMed  CAS  Google Scholar 

  • Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949

    Article  PubMed  CAS  Google Scholar 

  • Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D et al (2004) Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin’s lymphoma. J Clin Oncol 22:4095–4102

    Article  PubMed  CAS  Google Scholar 

  • Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D et al (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115:3623–3633

    Article  PubMed  CAS  Google Scholar 

  • Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A et al (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204:1257–1265

    Article  PubMed  CAS  Google Scholar 

  • Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP et al (2005) Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201:1591–1602

    Article  PubMed  CAS  Google Scholar 

  • Erfani N, Mehrabadi SM, Ghayumi MA, Haghshenas MR, Mojtahedi Z, Ghaderi A et al (2012) Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer 77:306–311

    Article  PubMed  Google Scholar 

  • Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R et al (2003) Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 4:1206–1212

    Article  PubMed  Google Scholar 

  • Figgitt DP, Lamb HM, Goa KL (2000) Denileukin diftitox. Am J Clin Dermatol 1:67–72 (discussion 3)

    Google Scholar 

  • Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat Immunol 4:330–336

    Article  PubMed  CAS  Google Scholar 

  • Foss FM (2000) DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin Lymphoma 1:110–117

    Article  PubMed  CAS  Google Scholar 

  • Foss F, Demierre MF, DiVenuti G (2005) A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 106:454–457

    Article  PubMed  CAS  Google Scholar 

  • Frankel AE, Surendranathan A, Black JH, White A, Ganjoo K, Cripe LD (2006) Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. Cancer 106:2158–2164

    Article  PubMed  CAS  Google Scholar 

  • Fujimoto S, Greene M, Sehon AH (1975) Immunosuppressor T cells in tumor bearing host. Immunol Commun 4:201–217

    PubMed  CAS  Google Scholar 

  • Gershon RK, Kondo K (1970) Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18:723–737

    PubMed  CAS  Google Scholar 

  • Gershon RK, Kondo K (1971) Infectious immunological tolerance. Immunology 21:903–914

    PubMed  CAS  Google Scholar 

  • Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C et al (2004) CD4+ CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34:336–344

    Article  PubMed  CAS  Google Scholar 

  • Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N et al (2005) CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202:1075–1085

    Article  PubMed  CAS  Google Scholar 

  • Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F et al (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641–648

    Article  PubMed  CAS  Google Scholar 

  • Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V et al (2009) Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69:2000–2009

    Article  PubMed  CAS  Google Scholar 

  • Gray CP, Arosio P, Hersey P (2003) Association of increased levels of heavy-chain ferritin with increased CD4+ CD25+ regulatory T-cell levels in patients with melanoma. Clin Cancer Res 9:2551–2559

    PubMed  CAS  Google Scholar 

  • Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ (2004) Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21:589–601

    Article  PubMed  CAS  Google Scholar 

  • Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, Reese ED, Herbstreith MH, Laping NJ et al (2004) SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 3:737–745

    PubMed  CAS  Google Scholar 

  • Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057–1061

    Article  PubMed  CAS  Google Scholar 

  • Huber S, Schramm C (2006) TGF-beta and CD4+ CD25+ regulatory T cells. Front Biosci 11:1014–1023

    Article  PubMed  CAS  Google Scholar 

  • Huehn J, Hamann A (2005) Homing to suppress: address codes for Treg migration. Trends Immunol 26:632–636

    Article  PubMed  CAS  Google Scholar 

  • Hurwitz AA, Yu TF, Leach DR, Allison JP (1998) CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A 95:10067–10071

    Article  PubMed  CAS  Google Scholar 

  • Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM et al (2000) Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60:2444–2448

    PubMed  CAS  Google Scholar 

  • Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H (2003) Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9:4404–4408

    PubMed  Google Scholar 

  • Ishida T, Iida S, Akatsuka Y, Ishii T, Miyazaki M, Komatsu H et al (2004) The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. Clin Cancer Res 10:7529–7539

    Article  PubMed  CAS  Google Scholar 

  • Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S et al (2006) Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 66:5716–5722

    Article  PubMed  CAS  Google Scholar 

  • Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ (2012) Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 13:e32–e42

    Article  PubMed  CAS  Google Scholar 

  • Jain N, Nguyen H, Chambers C, Kang J (2010) Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci U S A 107:1524–1528

    Article  PubMed  Google Scholar 

  • Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB (2008) Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 57:123–131

    Article  PubMed  CAS  Google Scholar 

  • Josefowicz SZ, Lu LF, Rudensky AY (2012) Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 30:531–564

    Article  PubMed  CAS  Google Scholar 

  • Ju S, Qiu H, Zhou X, Zhu B, Lv X, Huang X et al (2009) CD13+ CD4+ CD25hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients. Cell Cycle 8:2578–2585

    Article  PubMed  CAS  Google Scholar 

  • Kawai M, Kitade H, Mathieu C, Waer M, Pirenne J (2005) Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T cells in vivo. Transplantation 79:1073–1077

    Article  PubMed  CAS  Google Scholar 

  • Kitamura N, Murata S, Ueki T, Mekata E, Reilly RT, Jaffee EM et al (2009) OX40 costimulation can abrogate Foxp3 + regulatory T cell-mediated suppression of antitumor immunity. Int J Cancer 125:630–638

    Article  PubMed  CAS  Google Scholar 

  • Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman MK, Whitesell LJ et al (2003) Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 63:1860–1864

    PubMed  CAS  Google Scholar 

  • Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM et al (2006) B7–H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A 103:10391–10396

    Article  PubMed  CAS  Google Scholar 

  • Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M et al (2005) CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 65:465–472

    PubMed  CAS  Google Scholar 

  • Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P et al (2006) B7–H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203:871–881

    Article  PubMed  CAS  Google Scholar 

  • Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P et al (2007) Relationship between B7–H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 67:8900–8905

    Article  PubMed  CAS  Google Scholar 

  • Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W et al (2009a) FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 69:3995–4000

    Article  PubMed  CAS  Google Scholar 

  • Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S et al (2009b) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114:1141–1149

    Article  PubMed  CAS  Google Scholar 

  • Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM et al (1997) Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 94:8099–8103

    Article  PubMed  CAS  Google Scholar 

  • Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM et al (1999) Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A 96:15074–15079

    Article  PubMed  CAS  Google Scholar 

  • Le DT, Jaffee EM (2012) Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 72:3439–3444

    Article  PubMed  CAS  Google Scholar 

  • Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734–1736

    Article  PubMed  CAS  Google Scholar 

  • Liu Y, Zhang P, Li J, Kulkarni AB, Perruche S, Chen W (2008) A critical function for TGF-beta signaling in the development of natural CD4+ CD25+ Foxp3+ regulatory T cells. Nat Immunol 9:632–640

    Article  PubMed  CAS  Google Scholar 

  • Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G et al (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756–2761

    PubMed  CAS  Google Scholar 

  • Lu L, Cantor H (2008) Generation and regulation of CD8(+) regulatory T cells. Cell Mol Immunol 5:401–406

    Article  PubMed  CAS  Google Scholar 

  • Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H (2005) Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862–2868

    Article  PubMed  CAS  Google Scholar 

  • Mahic M, Henjum K, Yaqub S, Bjornbeth BA, Torgersen KM, Tasken K et al (2008) Generation of highly suppressive adaptive CD8(+)CD25(+)FOXP3(+) regulatory T cells by continuous antigen stimulation. Eur J Immunol 38:640–646

    Article  PubMed  CAS  Google Scholar 

  • Mahnke K, Schonfeld K, Fondel S, Ring S, Karakhanova S, Wiedemeyer K et al (2007) Depletion of CD4+ CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 120:2723–2733

    Article  PubMed  CAS  Google Scholar 

  • Mailloux AW, Clark AM, Young MR (2010) NK depletion results in increased CCL22 secretion and Treg levels in Lewis lung carcinoma via the accumulation of CCL22-secreting CD11b+ CD11c+ cells. Int J Cancer 127:2598–2611

    Article  PubMed  CAS  Google Scholar 

  • Maker AV, Attia P, Rosenberg SA (2005) Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 175:7746–7754

    PubMed  CAS  Google Scholar 

  • Maloy KJ, Salaun L, Cahill R, Dougan G, Saunders NJ, Powrie F (2003) CD4+ CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med 197:111–119

    Article  PubMed  CAS  Google Scholar 

  • Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J et al (2010) Generation and accumulation of immunosuppressive adenosine by human CD4+ CD25highFOXP3+ regulatory T cells. J Biol Chem 285:7176–7186

    Article  PubMed  CAS  Google Scholar 

  • Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN et al (2004) Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103:1755–1762

    Article  PubMed  CAS  Google Scholar 

  • Matar P, Rozados VR, Gervasoni SI, Scharovsky OG (2001) Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response. Int Immunopharmacol 1:307–319

    Article  PubMed  CAS  Google Scholar 

  • Mellor AL, Munn DH (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4:762–774

    Article  PubMed  CAS  Google Scholar 

  • Menard C, Ghiringhelli F, Roux S, Chaput N, Mateus C, Grohmann U et al (2008) Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res 14:5242–5249

    Article  PubMed  CAS  Google Scholar 

  • Menetrier-Caux C, Curiel T, Faget J, Manuel M, Caux C, Zou W (2012) Targeting regulatory T cells. Target Oncol 7:15–28

    Article  PubMed  Google Scholar 

  • Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E et al (2010) Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res 16:2781–2791

    Article  PubMed  CAS  Google Scholar 

  • Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC (2010) Regulatory T cells in cancer. Adv Cancer Res 107:57–117

    Article  PubMed  CAS  Google Scholar 

  • Nocentini G, Riccardi C (2005) GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily. Eur J Immunol 35:1016–1022

    Article  PubMed  CAS  Google Scholar 

  • North RJ (1982) Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155:1063–1074

    Article  PubMed  CAS  Google Scholar 

  • Okawaki M, Yamaguchi Y, Okita R, Ohara M, Okada M (2008) Dose-finding study of anti-CD25 antibody for targeting regulatory T cells in locoregional immunotherapy of malignant effusion. Hiroshima J Med Sci 57:37–46

    PubMed  CAS  Google Scholar 

  • Olkhanud PB, Baatar D, Bodogai M, Hakim F, Gress R, Anderson RL et al (2009) Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res 69:5996–6004

    Article  PubMed  CAS  Google Scholar 

  • Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E et al (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376–388

    PubMed  CAS  Google Scholar 

  • Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128–3133

    PubMed  CAS  Google Scholar 

  • Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ (2007) CD4+ CD25+ Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 8:1353–1362

    Article  PubMed  CAS  Google Scholar 

  • Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP (2009) Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206:1717–1725

    Article  PubMed  CAS  Google Scholar 

  • Peng DJ, Liu R, Zou W (2012) Regulatory T cells in human ovarian cancer. J Oncol 2012:345164

    Article  PubMed  CAS  Google Scholar 

  • Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372–8377

    Article  PubMed  CAS  Google Scholar 

  • Piconese S, Valzasina B, Colombo MP (2008) OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 205:825–839

    Article  PubMed  CAS  Google Scholar 

  • Rech AJ, Vonderheide RH (2009) Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 1174:99–106

    Article  PubMed  CAS  Google Scholar 

  • Rico MJ, Rozados VR, Mainetti LE, Zacarias Fluck MF, Matar P, Scharovsky OG (2012) Regulatory T cells but not NKT I cells are modulated by a single low-dose cyclophosphamide in a B cell lymphoma tumor-model. Exp Oncol 34:38–42

    PubMed  CAS  Google Scholar 

  • Rollinghoff M, Starzinski-Powitz A, Pfizenmaier K, Wagner H (1977) Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J Exp Med 145:455–459

    Article  PubMed  CAS  Google Scholar 

  • Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6:345–352

    Article  PubMed  CAS  Google Scholar 

  • Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151–1164

    PubMed  CAS  Google Scholar 

  • Schlingensiepen KH, Fischer-Blass B, Schmaus S, Ludwig S (2008) Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res 177:137–150

    Article  PubMed  CAS  Google Scholar 

  • Schott AK, Pries R, Wollenberg B (2010) Permanent up-regulation of regulatory T-lymphocytes in patients with head and neck cancer. Int J Mol Med 26:67–75

    PubMed  CAS  Google Scholar 

  • Sharabi A, Ghera NH (2010) Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy. Adv Cancer Res 107:1–37

    Article  PubMed  CAS  Google Scholar 

  • Shevach EM (2009) Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30:636–645

    Article  PubMed  CAS  Google Scholar 

  • Shevach EM, Stephens GL (2006) The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? Nat Rev Immunol 6:613–618

    Article  PubMed  CAS  Google Scholar 

  • Shibutani S, Inoue F, Aramaki O, Akiyama Y, Matsumoto K, Shimazu M et al (2005) Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. Transplantation 79:904–913

    Article  PubMed  CAS  Google Scholar 

  • Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S (2002) Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3:135–142

    Article  PubMed  CAS  Google Scholar 

  • Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S et al (2002) Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 62:5267–5272

    PubMed  CAS  Google Scholar 

  • Strauss L, Bergmann C, Szczepanski MJ, Lang S, Kirkwood JM, Whiteside TL (2008) Expression of ICOS on human melanoma-infiltrating CD4+ CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol 180:2967–2980

    PubMed  CAS  Google Scholar 

  • Strauss L, Bergmann C, Whiteside TL (2009) Human circulating CD4+ CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol 182:1469–1480

    PubMed  CAS  Google Scholar 

  • Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP et al (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823–832

    Article  PubMed  CAS  Google Scholar 

  • Taieb J, Chaput N, Schartz N, Roux S, Novault S, Menard C et al (2006) Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol 176:2722–2729

    PubMed  CAS  Google Scholar 

  • Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M et al (1998) Immunologic self-tolerance maintained by CD25+ CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10:1969–1980

    Article  PubMed  CAS  Google Scholar 

  • Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE et al (2009) Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 182:1746–1755

    PubMed  CAS  Google Scholar 

  • Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA (2004) Distinct roles of CTLA-4 and TGF-beta in CD4+ CD25+ regulatory T cell function. Eur J Immunol 34:2996–3005

    Article  PubMed  CAS  Google Scholar 

  • Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454

    Article  PubMed  CAS  Google Scholar 

  • Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN (2004) Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200:771–782

    Article  PubMed  CAS  Google Scholar 

  • van Elsas A, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355–366

    Article  PubMed  Google Scholar 

  • Wang YM, Alexander SI (2009) CD8 regulatory T cells: what’s old is now new. Immunol Cell Biol 87:192–193

    Article  PubMed  CAS  Google Scholar 

  • Wang J, Ke XY (2011) The four types of Tregs in malignant lymphomas. J Hematol Oncol 4:50

    Article  PubMed  Google Scholar 

  • Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, Noelle RJ (2008) Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+ CD4+ regulatory T cells. Proc Natl Acad Sci U S A 105:9331–9336

    Article  PubMed  Google Scholar 

  • Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J (2009) PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol 21:1065–1077

    Article  PubMed  CAS  Google Scholar 

  • Wang W, Hodkinson P, McLaren F, Mackinnon A, Wallace W, Howie S et al (2012) Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3(+) cells in tumour infiltrate. Int J Cancer 131:E928–E937

    Article  PubMed  CAS  Google Scholar 

  • Weber J (2007) Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12:864–872

    Article  PubMed  CAS  Google Scholar 

  • Wei S, Kryczek I, Zou W (2006) Regulatory T-cell compartmentalization and trafficking. Blood 108:426–431

    Article  PubMed  CAS  Google Scholar 

  • Whiteside TL, Mandapathil M, Schuler P (2011) The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg). Curr Med Chem 18:5217–5223

    Article  PubMed  CAS  Google Scholar 

  • Wilke CM, Wu K, Zhao E, Wang G, Zou W (2010) Prognostic significance of regulatory T cells in tumor. Int J Cancer 127:748–758

    PubMed  CAS  Google Scholar 

  • Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606–612

    PubMed  Google Scholar 

  • Won J, Kim H, Park EJ, Hong Y, Kim SJ, Yun Y (1999) Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy. Cancer Res 59:1273–1277

    PubMed  CAS  Google Scholar 

  • Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G et al (2001a) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61:4766–4772

    PubMed  CAS  Google Scholar 

  • Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G et al (2001b) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early- stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61:4766–4772

    PubMed  CAS  Google Scholar 

  • Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K et al (2010) Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 28:1591–1598

    Article  PubMed  CAS  Google Scholar 

  • Ye ZJ, Zhou Q, Zhang JC, Li X, Wu C, Qin SM et al (2011) CD39+ regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism. Respir Res 12:77

    Article  PubMed  CAS  Google Scholar 

  • Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM, Schlom J et al (2008) Enhanced functionality of CD4+ CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 14:1032–1040

    Article  PubMed  CAS  Google Scholar 

  • Zabransky DJ, Nirschl CJ, Durham NM, Park BV, Ceccato CM, Bruno TC et al (2012) Phenotypic and functional properties of Helios + regulatory T cells. PLoS ONE 7:e34547

    Article  PubMed  CAS  Google Scholar 

  • Zhao E, Wang L, Dai J, Kryczek I, Wei S, Vatan L et al (2012) Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology 1:152–161

    Article  PubMed  Google Scholar 

  • Zhou G, Levitsky HI (2007) Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol 178:2155–2162

    PubMed  CAS  Google Scholar 

  • Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295–307

    Article  PubMed  CAS  Google Scholar 

  • Zou W, Lackner AA, Simon M, Durand-Gasselin I, Galanaud P, Desrosiers RC et al (1997) Early cytokine and chemokine gene expression in lymph nodes of macaques infected with simian immunodeficiency virus is predictive of disease outcome and vaccine efficacy. J Virol 71:1227–1236

    PubMed  CAS  Google Scholar 

  • Zou L, Barnett B, Safah H, Larussa VF, Evdemon-Hogan M, Mottram P et al (2004) Bone marrow is a reservoir for CD4+ CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 64:8451–8455

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of Michigan School of Medicine, C560B MSRB II, 1150 W. Medical Center Dr., Ann Arbor, MI, 48109-0669, USA

    Wei Wang & Weiping Zou

Authors
  1. Wei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Weiping Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Weiping Zou .

Editor information

Editors and Affiliations

  1. Department of Pathology, University of Pittsburgh Medical Center, 3550 Terrace Street Scaife Hal, Pittsburgh, 15213, Pennsylvania, USA

    Michael R. Shurin

  2. , Clinical Cooperation Unit Dermato-Oncolo, German Cancer Research Center, Im Neuenheimer Feld 280, Heidelberg, 69120, Germany

    Viktor Umansky

  3. , SAIC-Frederick, Inc., National Cancer Institute at Frederick, Post Office B, Frederick, 21702, Maryland, USA

    Anatoli Malyguine

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Wang, W., Zou, W. (2013). Therapeutic Targeting Regulatory T Cells in Tumor. In: Shurin, M., Umansky, V., Malyguine, A. (eds) The Tumor Immunoenvironment. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6217-6_25

Download citation

Publish with us

Policies and ethics

Search

Navigation